Characteristics, accessibility and regional equity evaluation of pediatric medicines through National Drug Price Negotiation of China, 2017–2024
Ming Hu
ObjectivesSince its inception in 2017, China’s National Drug Price Negotiation (NDPN) has served as a crucial mechanism for the strategic procurement of innovative medicines, with pediatric medicines representing a key and prioritized area. This study aims to systematically analyze the inclusion of pediatric medicines in the National Reimbursement Drug List (NRDL) through negotiation from 2017 to 2024, evaluate their current accessibility and regional equity, and provide evidence to support deci